In vitro activities of polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii [3]

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 2, 2006, Pages 825-

  Wareham, D W ^a   Bean, D C ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMIPENEM; POLYMYXIN B; RIFAMPICIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC THERAPY; BACTEREMIA; CRITICALLY ILL PATIENT; DRUG POTENTIATION; LETTER; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; PNEUMONIA; PRIORITY JOURNAL; SEPSIS;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; IMIPENEM; MICROBIAL SENSITIVITY TESTS; POLYMYXIN B; RIFAMPIN;

EID: 31944452565     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.2.825-826.2006     Document Type: Letter

References (11)

1. American Society for Microbiology. 2005. Instructions to authors. Antimicrob. Agents Chemother. 49:1-20.
2. Coelho, J., N. Woodford, J. Turton, and D. M. Livermore. 2004. Multiresistant Acinetobacter in the UK: how big a threat? J. Hosp. Infect. 58:167-169.
3. Jane, R. L., and H. Danziger. 2004. Multidrug resistant Acinetobacter infections: an emerging challenge to clinicians. Ann. Pharmacother. 38:1449-1459.
4. Montero, A., J. Ariza, X. Corbella, A. Domenach, C. Cabellos, J. Ayats, F. Tubau, C. Borraz, and F. Gudiol. 2004. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J. Antimicrob. Chemother. 54:1085-1091.
5. Odds, F. C. 2003. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 52:1.
6. Rand, K. H., H. J. Houck, P. Brown, and D. Bennett. 1993. Reproducibility of the microdilution checkerboard method for antibiotic synergy. Antimicrob. Agents Chemother. 37:613-615.
7. Yoon, J., C. Urban, C. Terzian, N. Mariano, and J. J. Rahal. 2004. In vitro double and triple synergistic activities of polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 48:753-757.
8. Berenbaum, M. C. 1988. Synergy and antagonism are not synonymous with therapeutic advantage and disadvantage. J. Antimicrob. Chemother. 21:497-499.
9. Berenbaum, M. C. 1978. A method for testing for synergy with any number of agents. J. Infect. Dis. 137:122-130.
10. Odds, F. C. 2003. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 52:1.
11. Yoon, J., C. Urban, C. Terzian, N. Mariano, and J. J. Rahal. 2004. In vitro double and triple synergistic activities of polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 48:753-757.